Free Trial

3,844 Shares in CVS Health Corporation (NYSE:CVS) Purchased by Callan Capital LLC

CVS Health logo with Medical background

Callan Capital LLC purchased a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,844 shares of the pharmacy operator's stock, valued at approximately $260,000.

Several other large investors also recently bought and sold shares of the stock. Whitebox Advisors LLC purchased a new stake in CVS Health during the fourth quarter worth approximately $249,000. Fairfax Financial Holdings Ltd. Can acquired a new stake in CVS Health during the fourth quarter worth approximately $121,742,000. Bank of New York Mellon Corp raised its holdings in CVS Health by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator's stock worth $608,481,000 after purchasing an additional 183,813 shares in the last quarter. Lazard Asset Management LLC raised its holdings in CVS Health by 7.3% during the fourth quarter. Lazard Asset Management LLC now owns 4,290,953 shares of the pharmacy operator's stock worth $192,617,000 after purchasing an additional 293,406 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in CVS Health by 248.0% during the first quarter. Teacher Retirement System of Texas now owns 282,232 shares of the pharmacy operator's stock worth $19,121,000 after purchasing an additional 201,120 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CVS. Robert W. Baird raised their price objective on shares of CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. UBS Group raised their price objective on shares of CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a report on Friday, May 2nd. Barclays set a $79.00 price objective on shares of CVS Health and gave the stock an "overweight" rating in a report on Monday, June 2nd. Royal Bank Of Canada raised their price objective on shares of CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a report on Monday, May 5th. Finally, Jefferies Financial Group lifted their target price on shares of CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a report on Monday, June 30th. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $75.06.

Check Out Our Latest Stock Report on CVS Health

Insider Activity at CVS Health

In related news, Director Guy P. Sansone bought 1,570 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the transaction, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.22% of the company's stock.

CVS Health Stock Performance

CVS traded down $1.08 during trading on Thursday, hitting $65.58. The stock had a trading volume of 6,326,674 shares, compared to its average volume of 10,798,099. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The firm has a market capitalization of $82.96 billion, a P/E ratio of 15.65, a PEG ratio of 0.95 and a beta of 0.57. The company's 50-day moving average price is $65.18 and its 200 day moving average price is $61.93. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. The company had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. CVS Health's revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 EPS. On average, equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.06%. CVS Health's payout ratio is currently 63.48%.

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Read More

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines